In Case You Missed It…

Quest Media is an innovative, adaptive lifestyle platform from MDA. With the power of this platform, we foster awareness and empowerment and have important conversations with experts, thought leaders, and members of the neuromuscular disease community about topics that matter to them and to the larger community of individuals with disabilities.

With so many valuable podcasts, blog articles, and magazine articles available to our audience, chances are that you may have missed one or two pieces of interesting content. Check out the summaries and links below.

In case you missed it… Quest Blogs:

FDA Approves First Muscle-Targeted Therapy for SMA: A Conversation with Dr. Se-Jin Lee

The FDA has approved Isembyld (apitegromab-mstn), the first therapy designed to target muscle health and regeneration in people living with spinal muscular atrophy (SMA). This milestone adds to the progress made by genetic therapies for SMA and provides families with a new option focused on improving muscle strength and daily function. To help families understand the science behind this breakthrough, Quest spoke with Dr. Se-Jin Lee, whose pioneering work on muscle biology paved the way for this therapy. Read more. 

Your Voice, Your Vote

For people living with disabilities participating in an election may require additional preparation. Questions about polling-place accessibility, transportation, voting equipment, personal assistance, and mail-in voting can become barriers if voters do not have reliable information early enough. MDA created Access the Vote campaign to help people living with neuromuscular diseases understand their voting rights, prepare to participate, and make their voices heard in the 2026 elections. Read more.

In case you missed it… Quest Podcast:

Episode 66: More CMT Clinical Trials Than Ever Before – Inside the Research Turning Point

In this episode of Quest Podcast, we chat with Sue Bruhn, PhD, CEO of the Charcot-Marie-Tooth Association (CMTA); Stephan Züchner, MD, PhD, Chief Genomics Officer at the University of Miami Miller School of Medicine; and Brian Lin, PhD, Senior Research Portfolio Director at the Muscular Dystrophy Association. Together, they break down what Charcot-Marie-Tooth disease (CMT) does to the peripheral nerves, why more than 100 different genes can cause it, and what separates a clinical diagnosis from a genetic one. They open up about the parts of living with CMT that research can overlook, from fatigue to the weight of seeing your own future in an older relative with CMT, and walk through the therapies now being tested, what the field has learned from trials that fell short, and how patients can get trial-ready today. Sue, Stephan, and Brian share their experiences, expertise, and genuine optimism about where CMT treatment is headed. Listen here.

In case you missed it…Quest Magazine:

Quest Magazine 2026, Issue 3 is Here!

 The third issue of Quest Magazine for 2026 is here! Read up on disability rights, research and drug development, respiratory care, finding an accessible OB/GYN, and more. Read more.